| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Diabetic patients are at a higher risk of dying from cancer than healthy individuals. In this study, we focused on cancer chemotherapy, and evaluated the efficacy and safety of oxaliplatin and fluorouracil (FOLFOX) in colorectal cancer, which is associated with a higher incidence and mortality in diabetic patients. Our retrospective clinical study and basic study using hyperglycemic model mice showed that FOLFOX chemotherapy itself was less effective in diabetic patients and animals, compared to that in those without diabetes. Survival was shorter in the hyperglycemic mice, regardless of FOLFOX treatment, than in the control mice. These findings would help the decision of therapeutic strategy and choice of chemotherapeutic regimen in colorectal cancer patients with diabetes.
|
